PP
RVLP

PDT Partners’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

PDT Partners’s Portfolio RVLP Stock Details RVLP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-13,165
Closed -$71K – 887
2020
Q3 		$71K Buy
+13,165
New +$75.8K ﹤0.01% 696

Other funds holding RVLP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

PDT Partners's RVLP Position: Q4 2020 in Review

PDT Partners sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q4 2020, closing a stake of 13,165 shares — an estimated $71K sold.

PDT Partners first reported a position in RVLP in Q3 2020 and held it in 1 quarter. The position peaked at $71K in Q3 2020. 60 funds tracked by Wall St. Rank hold RVLP as of Q4 2020.

  • PDT Partners reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q4 2020 after selling out during the quarter.
  • PDT Partners sold 13,165 RVL Pharmaceuticals plc Ordinary Shares shares in Q4 2020, an estimated $71K.
  • PDT Partners first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q3 2020 and held it in 1 quarter.
  • PDT Partners's RVL Pharmaceuticals plc Ordinary Shares position peaked at $71K in Q3 2020.
  • 60 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q4 2020.

Based on PDT Partners's 13F filing for Q4 2020, filed 16 Feb 2021.